The influence of CYP3A gene polymorphisms on cyclosporine dose requirement in renal allograft recipients

Kidney International

Volumn 69, Issue 10, 2006, Pages 1858-1864

  Eng, H S ^a   Mohamed, Z ^a   Calne, R ^b   Lang, C C ^c   Mohd, M A ^a   Seet, W T ^a   Tan, S Y ^a,d  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b Department of Surgery ^*  (United Kingdom)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

Author keywords

Cyclosporine; CYP3A; Gene polymorphism; Renal allograft

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; CYTOCHROME P450 3A; CYTOCHROME P450 3AP1; CYTOCHROME P450 ISOENZYME; PREDNISOLONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONCENTRATION TO DOSE RATIO; DRUG BLOOD LEVEL; DRUG CONCENTRATION; DRUG DOSE; ENZYME ACTIVITY; ENZYME SUBSTRATE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; MAJOR CLINICAL STUDY; MALE; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; COHORT STUDIES; CYCLOSPORINE; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; SEX FACTORS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 33646681672     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000325     Document Type: Article

References (39)

1. Kahan BD, Welsh M, Schoenberg L et al. Variable oral absorption of cyclosporine: a biopharmaceutical risk factor for chronic renal allograft rejection. Transplantation 1996; 62: 599-606.
2. Calne R. Future concepts in transplantation. Transplant Proc 1999; 31(Suppl 1/2A): 21S-24S.
3. Canafax DM. Minimizing cyclosporine concentration variability to optimize transplant outcome. Clin Transplant 1995; 9: 1-13.
4. Yates CR, Zhang WH, Song PF et al. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. Pharmacogenetics 2003; 43: 555-564.
5. Kronbach T, Fisher V, Meyer UA. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolising enzymes explains interactions of cyclosporine with other drug. Clin Pharmacol Ther 1988; 43: 630-635.
6. Aoyama T, Yamano S, Waxman DJ et al. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequences and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J Biol Chem 1989; 264: 10388-10395.
7. Wrighton SA, Ring BJ, Watkins PB et al. Identification of a polymorphically expressed member of the human cytochrome P-450III family. Mol Pharmacol 1989; 36: 97-105.
8. Kitada M, Kamataki T, Itahashi K et al. Purification and properties of the cytochrome P-450 from homogenates of human fetal livers. Arch Biochem Biophys 1985; 241: 275-280.
9. Komori M, Nishio K, Ohi H et al. Molecular cloning and sequence analysis of cDNA containing the entire coding region for human fetal liver cytochrome P-450. J Biochem (Tokyo) 1989; 105: 161-163.
10. Domanshi TL, Finta C, Halpert JR et al. cDNA cloning and initial characterization of the CYP3A43, a novel human cytochrome P450. Mol Pharmacol 2001; 59: 386-392.
11. Hesselink DA, van Schaik RHN, van der Heiden IP et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmakinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245-254.
12. Hoyo-Vadillo C, Castenada-Hernandez G, Herrera JE et al. Pharmacokinetics of nifedipine slow release tablets in Mexican patients: further evidence for an oxidative polymorphism. J Clin Pharmacol 1989; 29: 816-820.
13. Renwick AG, Robertson DRC, Macklin B et al. The pharmacokinetics of oral nifedipine - a population study. Br J Clin Pharmacol 1988; 25: 701-708.
14. Schellens JHM, Soons PA, Breimer DD. Lack of biomodality in nifedipine plasma kinetics in a large population of healthy subjects. Biochem Pharmacol 1988; 37: 2507-2510.
15. Lamba JK, Lin YS, Schuetz EG et al. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54: 1271-1294.
16. Paine MF, Khalighi M, Fisher JM et al. Characterization of inter- and intra-intestinal differences in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 1997; 283: 1552-1562.
17. Kuehl P, Zhang J, Lin Y et al. Sequence diversity in CYP3A promoters and characterization of the genomic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 207: 383-391.
18. Lin Y, Dowling A, Quigley S et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 2002; 62: 162-172.
19. Lee SJ, Usmani KA, Chanas B et al. Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics 2003; 13: 461-472.
20. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 1999; 37: 485-505.
21. Finta C, Zaphiropoulos PG. The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons. Gene 2000; 260: 13-23.
22. Paulussen A, Lavrijsen K, Bohets H et al. Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans. Pharmacogenetics 2000; 10: 415-424.
23. Hustert E, Haberl M, Burk O et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11: 773-779.
24. Min DI, Lee M, Ku Y et al. Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers. Clin Pharmacol Ther 2000; 68: 478-486.
25. Lindholm A, Welsh M, Alton C et al. Demographic factors influencing cyclosporine pharmacokinetics parameters in patients with uremia: racial differences in bioavailability. Clin Pharmacol Ther 1992; 52: 359-371.
26. First MR, Schroeder TJ, Monaco AP et al. Cyclosporine bioavailability: dosing implications and impact on clinical outcomes in select transplantation subpopulations. Clin Transplant 1996; 10: 55-59.
27. Dunn J, Vathsala A, Golden A et al. Impact of race on the outcome of renal transplantation under cyclosporine-prednisolone. Transplant Proc 1986; 21: 3946.
28. Devlin JJ, O'grady JG, Tan KC et al. Ethnic variations in patient and graft survival after liver transplantation. Transplantation 1993; 56: 1381-1384.
29. Waiser J, Slowinski T, Brinker-Paschke A et al. Impact of the variability of cyclosporine A trough levels on long-term renal allograft function. Nephrol Dial Transplant 2002; 17: 1310-1317.
30. Soin AS, Rasmussen A, Jamieson NV et al. Cyclosporine levels in the early posttransport period: predictive of chronic rejection in liver transplantation ? Transplant Proc 1995; 27: 1129-1130.
31. Macphee IAM, Fredericks S, Tai T et al. Tacrolimus Pharmacogenetics: polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002; 74: 1486-1489.
32. Thervet E, Anglicheau D, King B et al. Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ration in renal transplant recipients. Transplantation 2003; 76: 1233-1235.
33. Haufroid V, Mourad M, Kerchove VV et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004; 14: 147-154.
34. Anglicheau D, Thervet E, Etienne I et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin. Pharmacol Ther 2004; 75: 422-433.
35. Hesselink DA, Van Gelder T, Van Schaik RHN et al. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4 and CYP3A5 genes. Clin Pharmacol Ther 2004; 76: 545-556.
36. Kahan BD, Kramer WG, Wideman C et al. Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay. Transplantation 1986; 41: 459-464.
37. Kasiske BL, Heim-Duthoy K, Rao KV, Awni WM. The relationship between cyclosporine pharmacokinetics parameters and subsequent acute rejection in renal transplant recipients. Transplantation 1988; 46: 716-722.
38. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993; 54: 205-218.
39. van Schaik RHN, van der Heiden IP, van den Anker JN et al. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 2002; 48: 1668-1671.